<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00037219</url>
  </required_header>
  <id_info>
    <org_study_id>VER002-6</org_study_id>
    <secondary_id>A8851018</secondary_id>
    <nct_id>NCT00037219</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.</brief_title>
  <official_title>A Phase 2, Open-Label, Randomized, Dose-Ranging Study of the Safety and Efficacy of Intravenous Anidulafungin (VER002) in the Treatment of Patients With Invasive Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vicuron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      Anidulafungin may be effective for the treatment of invasive Candida infections. The purpose
      of the study is to find the balance between dose tolerance and effectiveness of several doses
      for the treatment of United States patients with invasive candidiasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">November 2002</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">120</enrollment>
  <condition>Candidiasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anidulafungin, VER002</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive culture plus at least one clinical sign and symptom consistent with invasive
             candidiasis preferably within 96 hours of the proposed first dose of study drug

          -  Life expectancy: greater than 72 hours

        Exclusion Criteria:

          -  Pregnant Females

          -  Treatment with other investigational drug(s) within 4 weeks

          -  Hypersensitivity to anidulafungin or echinocandin therapy

          -  Hypersensitivity to Tween 80 (polysorbate 80) or tartaric acid
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Versicor, Inc.</name>
      <address>
        <city>King of Prussia</city>
        <state>Pennsylvania</state>
        <zip>19406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2002</study_first_submitted>
  <study_first_submitted_qc>May 16, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2002</study_first_posted>
  <last_update_submitted>October 17, 2008</last_update_submitted>
  <last_update_submitted_qc>October 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Anidulafungin</keyword>
  <keyword>Candidemia</keyword>
  <keyword>Invasive Candidiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anidulafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

